Johnson & Johnson Eyes $14 Billion Deal for Intra-Cellular Therapies, Valued at $10 Billion

Jan 12, 2025, 10:12 PM

Johnson & Johnson is exploring a potential acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on treatments for central nervous system disorders. The move could represent the largest biotech deal in over a year, with Intra-Cellular's market capitalization standing at approximately $10 billion following a recent jump. The discussions are ongoing, and no deal is certain, but the acquisition could break the drought of major biotech deals in 2024. The interest in Intra-Cellular comes after the company resolved an intellectual property overhang on Friday, potentially paving the way for this deal. If completed, the transaction is estimated to be valued at around $14 billion, which would be considered a fair price post-IP settlement.